These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25625919)

  • 1. Gene therapy for human colorectal cancer cell lines with recombinant adenovirus 5 based on loss of the insulin-like growth factor 2 imprinting.
    Sun H; Pan Y; He B; Deng Q; Li R; Xu Y; Chen J; Gao T; Ying H; Wang F; Liu X; Wang S
    Int J Oncol; 2015 Apr; 46(4):1759-67. PubMed ID: 25625919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system.
    Nie ZL; Pan YQ; He BS; Gu L; Chen LP; Li R; Xu YQ; Gao TY; Song GQ; Hoffman AR; Wang SK; Hu JF
    Mol Cancer; 2012 Nov; 11():86. PubMed ID: 23171475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for cancer through adenovirus vector‑mediated expression of the Ad5 early region gene 1A based on loss of IGF2 imprinting.
    Pan Y; He B; Lirong Z; Nie Z; Chen L; Gu L; Hoffman AR; Wang S; Hu J
    Oncol Rep; 2013 Oct; 30(4):1814-22. PubMed ID: 23900345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of recombinant adenovirus Ad-DT-A in targeted therapy for malignant cancer cell lines with loss of IGF2 imprinting].
    Pan YQ; He BS; Zhu C; Qu LL; Xu XF; Wang SK
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):816-21. PubMed ID: 22335945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for colorectal cancer by adenovirus-mediated siRNA targeting CD147 based on loss of the IGF2 imprinting system.
    Pan Y; He B; Chen J; Sun H; Deng Q; Wang F; Ying H; Liu X; Lin K; Peng H; Xie H; Wang S
    Int J Oncol; 2015 Nov; 47(5):1881-9. PubMed ID: 26397886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted tumor gene therapy based on loss of IGF2 imprinting.
    Pan Y; He B; Li T; Zhu C; Zhang L; Wang B; Xu Y; Qu L; Hoffman AR; Wang S; Hu J
    Cancer Biol Ther; 2010 Aug; 10(3):290-8. PubMed ID: 20592487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
    Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
    Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
    Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
    Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting gene-virus-mediated manganese superoxide dismutase effectively suppresses tumor growth in hepatocellular carcinoma in vitro and in vivo.
    Huang F; Ma B; Wang Y; Xiao R; Kong Y; Zhou X; Xia D
    Cancer Biother Radiopharm; 2014 Dec; 29(10):403-11. PubMed ID: 25414976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel oncolytic adenovirus based on simian adenovirus serotype 24.
    Cheng T; Song Y; Zhang Y; Zhang C; Yin J; Chi Y; Zhou D
    Oncotarget; 2017 Apr; 8(16):26871-26885. PubMed ID: 28460470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
    Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
    Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
    Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY
    Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic Suppression Effect on Tumor Growth of Colorectal Cancer by Combining Radiotherapy With a TRAIL-Armed Oncolytic Adenovirus.
    Gao H; Zhang X; Ding Y; Qiu R; Hong Y; Chen W
    Technol Cancer Res Treat; 2019; 18():1533033819853290. PubMed ID: 31138083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
    Lei W; Liu HB; Wang SB; Zhou XM; Zheng SD; Guo KN; Ma BY; Xia YL; Tan WS; Liu XY; Wang YG
    Acta Pharmacol Sin; 2013 Apr; 34(4):531-40. PubMed ID: 23503473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
    Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
    Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.